vs
GLOBUS MEDICAL INC（GMED）与RANGE RESOURCES CORP（RRC）财务数据对比。点击上方公司名可切换其他公司
GLOBUS MEDICAL INC的季度营收约是RANGE RESOURCES CORP的1.1倍（$826.4M vs $786.9M），RANGE RESOURCES CORP净利率更高（22.8% vs 17.0%，领先5.7%），GLOBUS MEDICAL INC同比增速更快（25.7% vs 18.0%），过去两年GLOBUS MEDICAL INC的营收复合增速更高（16.7% vs 14.6%）
Globus Medical是总部位于美国宾夕法尼亚州奥杜邦的上市骨科医疗器械企业，专注于相关产品的设计、研发与商业化，助力外科医生为肌肉骨骼系统疾病患者提供治疗方案，促进患者康复。
Range Resources Corporation是一家总部位于美国得克萨斯州沃斯堡的天然气勘探开采企业，核心运营区域为马塞勒斯页岩地层，是该地区拥有土地面积最大的运营商，专注于天然气资源的勘探、开发与生产业务，在北美油气开发领域具备深厚的行业积累。
GMED vs RRC — 直观对比
营收规模更大
GMED
是对方的1.1倍
$786.9M
营收增速更快
GMED
高出7.8%
18.0%
净利率更高
RRC
高出5.7%
17.0%
两年增速更快
GMED
近两年复合增速
14.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $826.4M | $786.9M |
| 净利润 | $140.6M | $179.1M |
| 毛利率 | 68.4% | 94.5% |
| 营业利润率 | 20.5% | — |
| 净利率 | 17.0% | 22.8% |
| 营收同比 | 25.7% | 18.0% |
| 净利润同比 | 430.4% | 88.8% |
| 每股收益（稀释后） | $1.01 | $0.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GMEDRRC
| Q4 25 | $826.4M | $786.9M | ||
| Q3 25 | $769.0M | $655.3M | ||
| Q2 25 | $745.3M | $699.6M | ||
| Q1 25 | $598.1M | $846.3M | ||
| Q4 24 | $657.3M | $667.0M | ||
| Q3 24 | $625.7M | $567.9M | ||
| Q2 24 | $629.7M | $513.2M | ||
| Q1 24 | $606.7M | $598.8M |
净利润GMEDRRC
| Q4 25 | $140.6M | $179.1M | ||
| Q3 25 | $119.0M | $144.3M | ||
| Q2 25 | $202.8M | $237.6M | ||
| Q1 25 | $75.5M | $97.1M | ||
| Q4 24 | $26.5M | $94.8M | ||
| Q3 24 | $51.8M | $50.7M | ||
| Q2 24 | $31.8M | $28.7M | ||
| Q1 24 | $-7.1M | $92.1M |
毛利率GMEDRRC
| Q4 25 | 68.4% | 94.5% | ||
| Q3 25 | 67.2% | 92.5% | ||
| Q2 25 | 66.6% | 95.0% | ||
| Q1 25 | 67.3% | 93.1% | ||
| Q4 24 | 59.9% | 93.7% | ||
| Q3 24 | 56.8% | 94.3% | ||
| Q2 24 | 58.7% | 93.4% | ||
| Q1 24 | 60.2% | 94.7% |
营业利润率GMEDRRC
| Q4 25 | 20.5% | — | ||
| Q3 25 | 17.9% | — | ||
| Q2 25 | 10.2% | — | ||
| Q1 25 | 16.2% | — | ||
| Q4 24 | 9.2% | — | ||
| Q3 24 | 7.7% | — | ||
| Q2 24 | 7.9% | — | ||
| Q1 24 | 1.3% | — |
净利率GMEDRRC
| Q4 25 | 17.0% | 22.8% | ||
| Q3 25 | 15.5% | 22.0% | ||
| Q2 25 | 27.2% | 34.0% | ||
| Q1 25 | 12.6% | 11.5% | ||
| Q4 24 | 4.0% | 14.2% | ||
| Q3 24 | 8.3% | 8.9% | ||
| Q2 24 | 5.0% | 5.6% | ||
| Q1 24 | -1.2% | 15.4% |
每股收益（稀释后）GMEDRRC
| Q4 25 | $1.01 | $0.75 | ||
| Q3 25 | $0.88 | $0.60 | ||
| Q2 25 | $1.49 | $0.99 | ||
| Q1 25 | $0.54 | $0.40 | ||
| Q4 24 | $0.19 | $0.38 | ||
| Q3 24 | $0.38 | $0.21 | ||
| Q2 24 | $0.23 | $0.12 | ||
| Q1 24 | $-0.05 | $0.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $557.2M | $204.0K |
| 总债务越低越好 | — | $1.2B |
| 股东权益账面价值 | $4.6B | $4.3B |
| 总资产 | $5.3B | $7.4B |
| 负债/权益比越低杠杆越低 | — | 0.28× |
8季度趋势，按日历期对齐
现金及短期投资GMEDRRC
| Q4 25 | $557.2M | $204.0K | ||
| Q3 25 | $18.8M | $175.0K | ||
| Q2 25 | — | $134.0K | ||
| Q1 25 | — | $344.6M | ||
| Q4 24 | $890.1M | $304.5M | ||
| Q3 24 | $71.9M | $277.4M | ||
| Q2 24 | $82.5M | $251.1M | ||
| Q1 24 | $80.4M | $343.1M |
总债务GMEDRRC
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | — | $1.7B | ||
| Q1 24 | — | $1.8B |
股东权益GMEDRRC
| Q4 25 | $4.6B | $4.3B | ||
| Q3 25 | $4.4B | $4.2B | ||
| Q2 25 | $4.3B | $4.1B | ||
| Q1 25 | $4.1B | $3.9B | ||
| Q4 24 | $4.2B | $3.9B | ||
| Q3 24 | $4.1B | $3.9B | ||
| Q2 24 | $4.0B | $3.9B | ||
| Q1 24 | $3.9B | $3.8B |
总资产GMEDRRC
| Q4 25 | $5.3B | $7.4B | ||
| Q3 25 | $5.1B | $7.2B | ||
| Q2 25 | $5.0B | $7.1B | ||
| Q1 25 | $4.7B | $7.4B | ||
| Q4 24 | $5.3B | $7.3B | ||
| Q3 24 | $5.1B | $7.2B | ||
| Q2 24 | $5.0B | $7.3B | ||
| Q1 24 | $4.9B | $7.4B |
负债/权益比GMEDRRC
| Q4 25 | — | 0.28× | ||
| Q3 25 | — | 0.29× | ||
| Q2 25 | — | 0.29× | ||
| Q1 25 | — | 0.43× | ||
| Q4 24 | — | 0.43× | ||
| Q3 24 | — | 0.44× | ||
| Q2 24 | — | 0.44× | ||
| Q1 24 | — | 0.46× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $248.6M | $257.5M |
| 自由现金流经营现金流 - 资本支出 | $202.4M | — |
| 自由现金流率自由现金流/营收 | 24.5% | — |
| 资本支出强度资本支出/营收 | 5.6% | — |
| 现金转化率经营现金流/净利润 | 1.77× | 1.44× |
| 过去12个月自由现金流最近4个季度 | $588.8M | — |
8季度趋势，按日历期对齐
经营现金流GMEDRRC
| Q4 25 | $248.6M | $257.5M | ||
| Q3 25 | $249.7M | $247.5M | ||
| Q2 25 | $77.9M | $336.2M | ||
| Q1 25 | $177.3M | $330.1M | ||
| Q4 24 | $210.3M | $217.9M | ||
| Q3 24 | $203.7M | $245.9M | ||
| Q2 24 | $54.3M | $148.8M | ||
| Q1 24 | $52.4M | $331.9M |
自由现金流GMEDRRC
| Q4 25 | $202.4M | — | ||
| Q3 25 | $213.9M | — | ||
| Q2 25 | $31.3M | — | ||
| Q1 25 | $141.2M | — | ||
| Q4 24 | $193.2M | — | ||
| Q3 24 | $161.7M | — | ||
| Q2 24 | $26.5M | — | ||
| Q1 24 | $23.8M | — |
自由现金流率GMEDRRC
| Q4 25 | 24.5% | — | ||
| Q3 25 | 27.8% | — | ||
| Q2 25 | 4.2% | — | ||
| Q1 25 | 23.6% | — | ||
| Q4 24 | 29.4% | — | ||
| Q3 24 | 25.8% | — | ||
| Q2 24 | 4.2% | — | ||
| Q1 24 | 3.9% | — |
资本支出强度GMEDRRC
| Q4 25 | 5.6% | — | ||
| Q3 25 | 4.7% | — | ||
| Q2 25 | 6.2% | — | ||
| Q1 25 | 6.0% | — | ||
| Q4 24 | 2.6% | — | ||
| Q3 24 | 6.7% | — | ||
| Q2 24 | 4.4% | — | ||
| Q1 24 | 4.7% | — |
现金转化率GMEDRRC
| Q4 25 | 1.77× | 1.44× | ||
| Q3 25 | 2.10× | 1.72× | ||
| Q2 25 | 0.38× | 1.42× | ||
| Q1 25 | 2.35× | 3.40× | ||
| Q4 24 | 7.94× | 2.30× | ||
| Q3 24 | 3.93× | 4.85× | ||
| Q2 24 | 1.71× | 5.18× | ||
| Q1 24 | — | 3.60× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GMED
| Other | $391.8M | 47% |
| Nevro Merger Agreement | $293.6M | 36% |
| Enabling Technologies | $141.0M | 17% |
RRC
| Natural Gas Natural Gas Liquids And Oil Sales | $745.5M | 95% |
| Brokered Natural Gas And Marketing | $41.3M | 5% |
